Do you want to read an article? Please log in or register.
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis
HepatitisHepatology
Related content
Inflammatory Bowel Disease
Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study
Clin Gastroenterol Hepatol
Devi J, Xu A, Stone M, Patel A, Khan A, Reddy N, Klein J, Chowla N, Benson C, Luu BC, Huang K, Jaiprada F, Fenster M, Ungaro R, Pekow J, Johnson AM, Yarur AJ, Shukla R, Huecker J, Bishu S, REBOOT IBD consortium, Deepak P
doi: 10.1016/j.cgh.2025.01.012
Hepatology
Non-alcohol-related cirrhosis leads to higher 6-week mortality after acute variceal bleeding than alcohol-related cirrhosis
Clin Gastroenterol Hepatol
Wong YJ, Buckholz A, Sim A, Teng M, Wong R, Curry MP, Anastasia DE Roza M, Baffy G, Teoh X, Chak E, Rustagi T, Chang J, Wee Wong G, Tandon P, Garcia-Tsao G, Abraldes JG, Mohanty A, Fortune B
doi: 10.1016/j.cgh.2024.10.022
Inflammatory Bowel Disease
Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study
Am J Gastroenterol
Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V
doi: 10.14309/ajg.0000000000003212
Inflammatory Bowel Disease
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data
BMC Gastroenterol
Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R
doi: 10.1186/s12876-025-04022-7
RECOMMENDED
Inflammatory Bowel Disease
Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Fuentes-Valenzuela E, Bastón-Rey I, García-Alonso FJ, Elosua A, Zabalza San Martín L, Leo Carnerero E, Garcia de la Filia I, Pedraza Pérez A, Sáiz Chumillas RM, Pascual Oliver A, Muñoz Villafranca C, Moreno V, Suárez Ferrer C, Molina G, Ferreiro-Iglesias R, Vega Villaamil P, Gardeazábal Mateos D, Segarra-Ortega JX, Garrido Marín A, Doallo AI, Alonso-Galán H, Brunet-Mas E, Jimenez García N, López Romero-Salazar F, Velayos B, Carballo-Folgoso L, Pérez Santamaría C, Mata Román L, Núñez Ortiz A, Barrio J, Barreiro-de Acosta M, Gutiérrez-Casbas A, Young GETECCU group
doi: 10.1093/ecco-jcc/jjaf058
Hepatology
The Effects of alfapump on Ascites Control and Quality of Life in Patients with Cirrhosis and Recurrent or Refractory Ascites
Am J Gastroenterol
Wong F, Vagas HE, Reddy KR, Pagadala MR, Pocha C, Sundaram V, Bajaj JS, Shlomovitz E, Bendel E, Capel J, Kamath PS, POSEIDON Study Group
doi: 10.14309/ajg.0000000000003300
Inflammatory Bowel Disease
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab
Adv Ther
Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D
doi: 10.1007/s12325-024-02942-6
Inflammatory Bowel Disease
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients
Inflamm Bowel Dis
Gebeyehu GG, Broglio G, Liu E, Limdi JK, Selinger C, Fiske J, Razanskaite V, Smith PJ, Flanagan PK, Subramanian S
doi: 10.1093/ibd/izae174
Inflammatory Bowel Disease
Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
J Crohns Colitis
Gros B, Constantine-Cooke N, Kennedy J, Elford AT, O'Hare C, Noble C, Jones GR, Arnott ID, Lees CW, Plevris N
doi: 10.1093/ecco-jcc/jjae188